Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Neurofibromatoses
Interventions: Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: coagulation factor VIIa [recombinant]-jncw; Drug
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 14,799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Breast Cancer, Triple Negative Breast Cancer
Interventions: hominex-2; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lymphoma
Interventions: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Berkeley, California • Duarte, California • Los Angeles, California + 22 more

Conditions: H1N1 Flu
Interventions: HAC1 Vaccine; Biological
Lead sponsor: Fraunhofer, Center for Molecular Biotechnology; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Occupational Stress
Interventions: Mindfulness Based Stress Reduction, Daily Examen spiritual practice, Stress inoculation combination; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infant Nutrition Disorders, Weight Loss, Postnatal Care, Premature Birth
Interventions: Woddle Smart Changing Pad; Device
Lead sponsor: Stan Kachnowski; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York

Conditions: Drug Abuse, Nicotine Dependence
Interventions: MagPro X100 Magnetic Stimulator, Transcranial Rotating Magnetic Stimulator, Magnetom Prisma Fit 3T Scanner; Device
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 17,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 271
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more

Conditions: Cystic Fibrosis
Interventions: RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions: Aripiprazole, Ingestible Event Marker (IEM); Drug · Device
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 12
States / cities: Cerritos, California • Garden Grove, California • Long Beach, California + 9 more

Conditions: Acute Coronary Syndrome
Interventions: EndoPAT testing (non invasive device), WatchPAT testing (non-invasive device); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: ibrutinib, Correlative laboratory samples, quality of life assessment; Drug · Other
Lead sponsor: Kami Maddocks, MD; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 3,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 116
States / cities: Phoenix, Arizona • Downey, California • Duarte, California + 92 more

Conditions: PTSD
Interventions: Virtual reality exposure therapy, 0.5 mg DEX; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cerebral Cavernous Malformation
Interventions: Atorvastatin, Placebo; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson Disease
Interventions: Standard of care + Mediterranean diet (intervention), Standard of care (control); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Depression, Bipolar I Disorder
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 69
States / cities: Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more

Conditions: Myelodysplastic Syndromes
Interventions: Deferasirox, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 11
States / cities: Anaheim, California • Greenwood Village, Colorado • Shreveport, Louisiana + 8 more

Conditions: Opioid Use, Unspecified
Interventions: Methadone, Fentanyl; Drug
Lead sponsor: Andrew Waberski; Other
Eligibility: 2 Years to 7 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Emotion Regulation, Mood Disorders, Stress Disorder, Anxiety Disorders, OCD, Impulse Control Disorder, Eating Disorders, Emotional Dysfunction, Emotional Instability, Emotional Distress, Emotional Maladjustment, Emotional Impulsivity, Obsessive-Compulsive Disorder, Emotion Dysregulation, Borderline Personality Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), electrical scalp stimulation, Cognitive Restructuring, Emotional Awareness Training; Device · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiovascular Diseases
Interventions: Delayed administration of survey modules, Regular administration of survey modules; Other
Lead sponsor: Boston University; Other
Eligibility: 50 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Framingham, Massachusetts

Conditions: Advanced Solid Tumors
Interventions: ADCT-901; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Denver, Colorado • New Haven, Connecticut • Atlanta, Georgia + 4 more

Search by objective public record fields.

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Study of the Safety and Immunogenicity of H1N1 Vaccine

Selah Trial of Stress Interventions for Clergy: Mindfulness Based Stress Reduction, Daily Examen, and Stress Inoculation

Feasibility and Validation of a Smart Changing Pad for Home Infant Weight Monitoring After Hospital Discharge

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Prediction of Cardiovascular Events in Vulnerable Patients Following Acute Coronary Syndrome

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery

Neurostimulation Versus Therapy for Problems With Emotions

Second eFramngham Heart Study

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors